1.Development stage and area
| Region | Exploratory Clinical Study Phase 2 |
Confirmatory Clinical Study Phase 3 |
NDA filed |
| Japan | Y-39983 Difluprednate |
Brimonidine |
|
| USA EU |
|||
| Asia | Tacrolimus<VKC> |
2.Product information
| Drug | Code name | Dosage Form | Mechanisum of action | Indication |
|---|---|---|---|---|
| Brimonidine tartrate | SNJ-2022 | Topical ophthalmic solution | Alpha-2 adrenergic agonist | Glaucoma |
| Y-39983 | SNJ-1656 | Topical ophthalmic solution | Rho kinase inhibitor | Glaucoma |
| Tacrolimus | FK 506 | Topical ophthalmic suspension | Ccalcineurin inhibitor | Vernal keratoconjunctivitis (VKC) |
| Difluprednate | SJE-2079 | Topical ophthalmic emulsion | Corticosteroid | Diabetic macular edema (DME) |
3.Additional information
| Brimonidine tartrate | Brimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow. BAC-free formulation. |
|---|---|
| Y-39983 | Y-39983 has a mechanism of action by increasing outflow of aqueous humor through the trabecular mechwork. |
| Tacrolimus | Tacrolimus is an immunosuppressive drug, and reduces cytokine production by T-cells. It has an excellent clinical effect against vernal keratoconjunctivitis as well as steriods. |
| Difluprednate | Difluprednate eye drop is a corticosteroid which has strong anti-inflammatory effect. Penetration of the drug into the eye is increased by unique emulsification technology. |
